Kips Bay Medical, Inc. (NASDAQ:KIPS) along with Manny Villafaña, its
Founder, Chairman and CEO today announced the closing of the
underwriters’ purchase from the Company of 475,000 shares of Company
common stock at a price of $0.65 per share pursuant to the
over-allotment option granted to the underwriters in connection with the
Company’s follow-on offering of common stock, which offering closed on
December 28, 2012. Sunrise Securities Corp. gave the Company notice of
the exercise on January 24, 2013. Sunrise Securities Corp. was the sole
book-running manager and Aegis Capital Corp. was a co-manager for the
A registration statement on Form S-1 relating to these securities was
declared effective by the Securities and Exchange Commission on December
21, 2012. A final prospectus relating to the offering was filed with the
SEC and is available on the SEC’s web site at http://www.sec.gov.
Copies of the final prospectus relating to the offering may also be
obtained from the offices of Sunrise Securities Corp., 600 Lexington
Ave., 23rd Floor, New York, New York 10022, telephone: (212) 421-1616 or
email: email@example.com, or
from the above-mentioned SEC website.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, these securities, nor will there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale is not permitted.
About Kips Bay Medical
Kips Bay Medical, Inc., founded in 2007 and headquartered in
Minneapolis, Minnesota, is a medical device company focused on
manufacturing and commercializing its external saphenous vein support
technology, or eSVS Mesh, for use in coronary artery bypass grafting
surgery. The eSVS Mesh is a nitinol mesh sleeve that, when placed over a
saphenous vein graft during CABG surgery, is designed to improve the
structural characteristics and long-term performance of the saphenous
vein graft. Additional information about Kips Bay Medical, Inc. can be
found at www.KipsBayMedical.com.